Lyra Therapeutics Inc [NASDAQ: LYRA] gained 3.89% or 0.4 points to close at $10.68 with a heavy trading volume of 116691 shares.
It opened the trading session at $10.21, the shares rose to $11.0355 and dropped to $9.81, the range by which the price of stock traded the whole day. The daily chart for LYRA points out that the company has recorded 16.98% gains over the past six months.
If we look at the average trading volume of 652.77K shares, LYRA reached to a volume of 116691 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here is what top equities market gurus are saying about Lyra Therapeutics Inc [LYRA]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for LYRA shares is $23.00 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on LYRA stock is a recommendation set at 3.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Jefferies have made an estimate for Lyra Therapeutics Inc shares, keeping their opinion on the stock as Hold, with their previous recommendation back on May 07, 2024. While these analysts kept the previous recommendation, H.C. Wainwright raised their target price from $12 to $2. The new note on the price target was released on May 07, 2024, representing the official price target for Lyra Therapeutics Inc stock.
The Average True Range (ATR) for Lyra Therapeutics Inc is set at 3.26, with the Price to Sales ratio for LYRA stock in the period of the last 12 months amounting to 11.89. The Price to Book ratio for the last quarter was 3.63, with the Price to Cash per share for the same quarter was set at 23.95.
Trading performance analysis for LYRA stock
Lyra Therapeutics Inc [LYRA] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -20.89. With this latest performance, LYRA shares gained by 99.81% in over the last four-week period, additionally plugging by 16.98% over the last 6 months – not to mention a drop of -27.64% in the past year of trading.
Lyra Therapeutics Inc [LYRA]: A deeper dive into fundamental analysis
Operating Margin for any stock indicates how profitable investing would be, and Lyra Therapeutics Inc [LYRA] shares currently have an operating margin of -3811.39% and a Gross Margin at 60.93%. Lyra Therapeutics Inc’s Net Margin is presently recorded at -6711.39%.
Return on Equity for this stock declined to -80.40%, with Return on Assets sitting at -80.40%.
Lyra Therapeutics Inc [LYRA]: An earnings per share (EPS) analysis
The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for LYRA. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Lyra Therapeutics Inc go to 42.99%.
An analysis of Institutional ownership at Lyra Therapeutics Inc [LYRA]
There are presently around $48.61%, or 49.01%% of LYRA stock, in the hands of institutional investors. The top three institutional holders of LYRA stocks are: PERCEPTIVE ADVISORS LLC with ownership of 12.76 million shares, which is approximately 19.4891%. CITADEL ADVISORS LLC, holding 4.77 million shares of the stock with an approximate value of $$1.32 million in LYRA stocks shares; and CITADEL ADVISORS LLC, currently with $$0.78 million in LYRA stock with ownership which is approximately 4.3232%.
